However, extensive mutational analysis of tumor genes could not identify predictive markers of regorafenib efficacy, including among genes involving in angiogenesis (FLT1, FLT2, FLT3, FLT4, KDR, TEK (TIE2), and VHL). The gene discussed is TEK; the disease is neoplasm.